Breast Cancer Research and Treatment

, Volume 47, Issue 3, pp 269–281

The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene

Authors

  • Adam J. Oates
    • Lombardi Cancer CenterGeorgetown University
  • Lisa M. Schumaker
    • Lombardi Cancer CenterGeorgetown University
  • Sara B. Jenkins
    • Lombardi Cancer CenterGeorgetown University
  • Amelia A. Pearce
    • Lombardi Cancer CenterGeorgetown University
  • Stacey A. DaCosta
    • Lombardi Cancer CenterGeorgetown University
  • Banu Arun
    • Lombardi Cancer CenterGeorgetown University
  • Matthew J.C. Ellis
    • Lombardi Cancer CenterGeorgetown University
Article

DOI: 10.1023/A:1005959218524

Cite this article as:
Oates, A.J., Schumaker, L.M., Jenkins, S.B. et al. Breast Cancer Res Treat (1998) 47: 269. doi:10.1023/A:1005959218524

Abstract

Loss of heterozygosity (LOH) at the mannose 6-phosphate/insulin-like growth factor 2 receptor gene locus (M6P/IGF2R) on 6q26-27 has recently been demonstrated in approximately 30% of both invasive and in situ breast cancers. LOH was coupled with somatic point mutations in the remaining allele in several instances, leading to the proposition that M6P/IGF2R is a tumor suppressor gene [1]. Somatic mutations in M6P/IGF2R have also been described in hepatoma [2] and gastrointestinal cancers with the replication error positive (RER+) phenotype [3]. These data indicate that M6P/IGF2R loss of function mutations may be involved in the pathogenesis of a wide spectrum of malignancies. Extensive data on the normal function of the M6P/IGF2R suggest that loss of M6P/IGF2R activity may contribute to multiple aspects of tumor pathophysiology, including deregulated growth, apoptosis, angiogenesis and invasion.

loss of heterozygositymannose 6-phosphate/insulin-like growth factor 2 receptormicrosatellite instabilitytumor suppressor gene

Copyright information

© Kluwer Academic Publishers 1998